1
|
Bencze N, Schvarcz C, Kriszta G, Danics L, Szőke É, Balogh P, Szállási Á, Hamar P, Helyes Z, Botz B. Desensitization of Capsaicin-Sensitive Afferents Accelerates Early Tumor Growth via Increased Vascular Leakage in a Murine Model of Triple Negative Breast Cancer. Front Oncol 2021; 11:685297. [PMID: 34336669 PMCID: PMC8317060 DOI: 10.3389/fonc.2021.685297] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2021] [Accepted: 06/18/2021] [Indexed: 11/13/2022] Open
Abstract
There is growing interest in the role of nerve-driven mechanisms in tumorigenesis and tumor growth. Capsaicin-sensitive afferents have been previously shown to possess antitumoral and immune-regulatory properties, the mechanism of which is currently poorly understood. In this study, we have assessed the role of these terminals in the triple negative 4T1 orthotopic mouse model of breast cancer. The ultrapotent capsaicin-analogue resiniferatoxin (RTX) was used for the selective, systemic desensitization of capsaicin-sensitive afferents. Growth and viability of orthotopically implanted 4T1 tumors were measured by caliper, in vivo MRI, and bioluminescence imaging, while tumor vascularity and protease enzyme activity were assessed using fluorescent in vivo imaging. The levels of the neuropeptides Calcitonin Gene-Related Peptide (CGRP), Substance P (SP), and somatostatin were measured from tumor tissue homogenates using radioimmunoassay, while tumor structure and peritumoral inflammation were evaluated by conventional use of CD31, CD45 and CD3 immunohistology. RTX-pretreated mice demonstrated facilitated tumor growth in the early phase measured using a caliper, which was coupled with increased tumor vascular leakage demonstrated using fluorescent vascular imaging. The tumor size difference dissipated by day seven. The MRI tumor volume was similar, while the intratumoral protease enzyme activity measured by fluorescence imaging was also comparable in RTX-pretreated and non-pretreated animals. Tumor viability or immunohistopathological profile was measured using CD3, CD31, and CD45 stains and did not differ significantly from the non-pretreated control group. Intratumoral somatostatin, CGRP, and SP levels were similar in both groups. Our results underscore the beneficial, antitumoral properties of capsaicin sensitive nerve terminals in this aggressive model of breast cancer, which is presumed to be due to the inhibition of tumor vascular bed disruption. The absence of any difference in intratumoral neuropeptide levels indicates non-neural sources playing a substantial part in their expression.
Collapse
Affiliation(s)
- Noémi Bencze
- Department of Pharmacology and Pharmacotherapy, University of Pécs Medical School, Pécs, Hungary.,János Szentágothai Research Centre, Molecular Pharmacology Research Team and Centre for Neuroscience, University of Pécs, Pécs, Hungary
| | - Csaba Schvarcz
- Institute of Translational Medicine, Semmelweis University, Budapest, Hungary
| | - Gábor Kriszta
- Department of Pharmacology and Pharmacotherapy, University of Pécs Medical School, Pécs, Hungary.,János Szentágothai Research Centre, Molecular Pharmacology Research Team and Centre for Neuroscience, University of Pécs, Pécs, Hungary
| | - Lea Danics
- Institute of Translational Medicine, Semmelweis University, Budapest, Hungary
| | - Éva Szőke
- Department of Pharmacology and Pharmacotherapy, University of Pécs Medical School, Pécs, Hungary.,János Szentágothai Research Centre, Molecular Pharmacology Research Team and Centre for Neuroscience, University of Pécs, Pécs, Hungary
| | - Péter Balogh
- Department of Immunology and Biotechnology, University of Pécs Medical School, Pécs, Hungary
| | - Árpád Szállási
- 1st Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary
| | - Péter Hamar
- Institute of Translational Medicine, Semmelweis University, Budapest, Hungary.,Institute for Translational Medicine, Medical School, University of Pécs, Pécs, Hungary
| | - Zsuzsanna Helyes
- Department of Pharmacology and Pharmacotherapy, University of Pécs Medical School, Pécs, Hungary.,János Szentágothai Research Centre, Molecular Pharmacology Research Team and Centre for Neuroscience, University of Pécs, Pécs, Hungary
| | - Bálint Botz
- János Szentágothai Research Centre, Molecular Pharmacology Research Team and Centre for Neuroscience, University of Pécs, Pécs, Hungary.,Department of Medical Imaging, University of Pécs, Medical School, Pécs, Hungary
| |
Collapse
|
2
|
Dank M, Balogh A, Benedek A, Besztercei B, Danics L, Forika G, Garay T, Hamar P, Karászi Á, Kaucsár T, Kiss É, Krenács T, Major E, Mohácsi R, Portörõ I, Ruisanchez É, Schvarcz C, Szász MA, Mbuotidem TJ, Vancsik T, Zolcsák Z, Benyó Z. [Preclinical and clinical investigation and development of electromagnetic oncological device - experience with solid tumors]. Magy Onkol 2019; 63:354-358. [PMID: 31821390] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2019] [Accepted: 11/28/2019] [Indexed: 06/10/2023]
Abstract
Our objective was to develop an electromagnetic tumor therapy device in a consortial cooperation between Semmelweis University and Oncotherm Ltd., to provide data and contribute to the development of the next generation of devices through preclinical, clinical and developmental modules via in vivo, in vitro studies, and patient treatments. Our numerous preclinical studies support the efficacy of mEHT. Clinical treatments were performed in 181 patients with inoperable and/or oligometastatic solid tumors. The protocols were developed, an international guideline was completed, and the planned steps of device development were realized. By optimizing previous selective RF techniques based on recent research findings, we can provide the most modern evidence-based treatment in the future.
Collapse
Affiliation(s)
- Magdolna Dank
- Onkológiai Központ, Semmelweis Egyetem, Budapest, Hungary
| | - Andrea Balogh
- Transzlációs Medicina Intézet, Semmelweis Egyetem, Budapest, Hungary.
| | - Anett Benedek
- Transzlációs Medicina Intézet, Semmelweis Egyetem, Budapest, Hungary.
| | - Balázs Besztercei
- Transzlációs Medicina Intézet, Semmelweis Egyetem, Budapest, Hungary.
| | - Lea Danics
- Transzlációs Medicina Intézet, Semmelweis Egyetem, Budapest, Hungary.
| | - Gertrud Forika
- I. Sz. Patológiai és Kísérleti Rákkutató Intézet, Semmelweis Egyetem, Budapest, Hungary
| | - Tamás Garay
- Információs Technológiai és Bionikai Kar, Pázmány Péter Katolikus Egyetem, Budapest, Hungary
| | - Péter Hamar
- Transzlációs Medicina Intézet, Semmelweis Egyetem, Budapest, Hungary.
| | - Ádám Karászi
- Onkológiai Központ, Semmelweis Egyetem, Budapest, Hungary
| | - Tamás Kaucsár
- Transzlációs Medicina Intézet, Semmelweis Egyetem, Budapest, Hungary.
| | - Éva Kiss
- Onkológiai Központ, Semmelweis Egyetem, Budapest, Hungary
| | - Tibor Krenács
- I. Sz. Patológiai és Kísérleti Rákkutató Intézet, Semmelweis Egyetem, Budapest, Hungary
| | - Enikõ Major
- Transzlációs Medicina Intézet, Semmelweis Egyetem, Budapest, Hungary.
| | - Réka Mohácsi
- Onkológiai Központ, Semmelweis Egyetem, Budapest, Hungary
| | - István Portörõ
- Transzlációs Medicina Intézet, Semmelweis Egyetem, Budapest, Hungary.
| | - Éva Ruisanchez
- Transzlációs Medicina Intézet, Semmelweis Egyetem, Budapest, Hungary.
| | - Csaba Schvarcz
- Transzlációs Medicina Intézet, Semmelweis Egyetem, Budapest, Hungary.
| | | | | | - Tamás Vancsik
- I. Sz. Patológiai és Kísérleti Rákkutató Intézet, Semmelweis Egyetem, Budapest, Hungary
| | - Zita Zolcsák
- Onkoradiológiai Osztály, Uzsoki Utcai Kórház, Budapest, Hungary
| | - Zoltán Benyó
- Transzlációs Medicina Intézet, Semmelweis Egyetem, Budapest, Hungary.
| |
Collapse
|
3
|
Hamar P, Danics L, Schvarcz C, Zolcsák Z, Benyó Z, Kaucsár T. Modulated electro hyperthermia inhibits tumor progression in a triple negative mouse breast cancer model. FASEB J 2019. [DOI: 10.1096/fasebj.2019.33.1_supplement.802.42] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|